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Abstract 
 
A MULTIFACETED APPROACH IDENTIFIES ERBB2 AND ERBB3 PROTEINS AND 
MICRORNA-125B AS KEY CONTRIBUTORS TO PROSTATE CANCER PROGRESSION  
by 
 
Danielle E. Weaver, BS 
  
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science 
in Bioinformatics at Virginia Commonwealth University. 
Virginia Commonwealth University, 2012  
 
 Prostate cancer is the most common cancer affecting men today. Therefore, there is a 
strong need for accurate biomarkers and successful therapeutic treatments. A novel approach 
combining a computationally built protein-protein interaction network of proven microRNA 
protein targets with high throughput proteomics identified ErbB2 and ErbB3 as key proteins in 
prostate cancer. These results coupled with microRNA array screening of an androgen-
independent prostate cancer progression model, substantiated by single microRNA analysis, 
suggested miR125b as a key tumor suppressor contributing to prostate cancer progression. 
miR125b expression was shown to be substantially increased in the non-tumorigenic P69 cell 
line compared to its highly tumorigenic, metastatic M12 variant. Luciferase reporter gene assays 
including the entire 3’UTR of either ErbB2 or ErbB3 revealed a 2.8- and 2.4-fold decrease 
(respectively) compared to control vector. Thus, this combinatorial approach has suggested an 
additional microRNA and its target involved in prostate tumor progression.   
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Chapter 1: Introduction 
The Prostate Organ: 
 The prostate organ is part of the male reproductive system and is located in front of the 
rectum and under the bladder. The prostate is an exocrine gland that produces two-thirds of the 
volume of seminal fluid. This fluid is alkaline in nature to help neutralize the acidity of the 
vagina, allowing sperm to survive longer and protect genetic material. During ejaculation, the 
prostate’s smooth muscles contract helping to expel the seminal fluid, carrying the sperm 
through the penis as semen.   
A healthy and mature prostate is roughly the size of a walnut and surrounds the urethra, 
the tube that passes urine from the bladder to the penis. In half of all men, around the age of fifty, 
the prostate begins to enlarge to abnormal size due to male hormones (androgens). This 
enlarging of the prostate can be classified as benign growth or malignant. Benign cases are often 
referred to as benign prostatic hyperplasia (BPH), where the prostate becomes enlarged and 
presses on the urethra slowing or stopping the flow of urine. This is non-cancerous and the 
overgrowth of these cells does not result in invasion into  other tissue. In malignant cases, the 
cells can invade or damage nearby tissue leading to cancer of the prostate gland.  
Incidence of Prostate Cancer in the United States: 
 Prostate Cancer is the most common cancer affecting men in the United States today with 
over 2.5 million identified manifestations 1. It is the second leading cause of cancer related 
deaths in American men 2. In 2012, it is estimated that 241,740 new cases of prostate cancer will 
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be diagnosed and 28,170 men will succumb to the disease 1. Essentially one in every six males in 
the U.S. will develop prostate cancer in their lifetime.  
The development of prostate cancer has been linked to age, race, and family history 2. 
Age is an important factor influencing the likelihood of contracting the disease. Nearly 65% of 
men diagnosed with prostate cancer are of age 65 or older. Figure 1-1 depicts the incidence of 
prostate cancer in all males according to age at the time of diagnosis per 100,000 men based on 
the data obtained from the National Cancer Institute Surveillance Epidemiology and End Results 
database
3
. Therefore, a man’s risk of developing prostate cancer increases as he ages and peaks 
between the ages of 70-74. It is remarkably uncommon for men to be diagnosed prior to the age 
of 50.   
In addition to age, a man’s race or ethnicity has a major influence on the probability of 
contracting the disease. On average, 156 out of every 100,000 males in the United States will be 
diagnosed with prostate cancer 3. White males have a lower than average overall incidence of 
prostate cancer of 149.5 out of every 100,000 males. African-American males have the highest 
overall incidence rate of 233.8 out of every 100,000. Figure 1-2 depicts the incidence of prostate 
cancer broken down by both age at the time of diagnosis and race/ethnicity per every 100,000 
males in the population 4. African-American men are three times more likely to die from prostate 
cancer than their white counterparts, while Asian-American men are the least likely race to 
contract the disease 2.  
Family history, as in most diseases, also plays a role in a man’s risk for developing 
prostate cancer. Men who have a single relative who was diagnosed with prostate cancer are 
twice as likely to develop the disease, while men with two or more relatives who have the  
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Figure 1-1: Variation in the incidence of prostate cancer based on age of patient. 
 Age is an important factor influencing the likelihood of contracting the disease. Nearly 65% of 
men diagnosed with prostate cancer are of age 65 or older 2. Men are most commonly diagnosed 
around age 70 and very infrequently diagnosed prior to the age of 50. Incidence is based on 
100,000 men. 
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Figure 1-1: Variation in the incidence of prostate cancer based on age of patient. 
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Figure 1-2: Variation in incidence of prostate cancer based on age and race/ethnicity.  
African-American males are much more likely to contract prostate cancer than any other race in 
the United States. Asian-American males are least likely to be diagnosed with the disease. All 
males are most commonly diagnosed around age 70. Incidence is based on 100,000 men. 
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Figure 1-2: Variation in incidence of prostate cancer based on age and race/ethnicity. 
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disease are four times as likely2. The men who are most susceptible are those whose family 
members were diagnosed prior to the age of 50 due to the rarity of the disease at younger ages. 
Prostate Cancer Detection: 
 In 1986 the U.S. Food and Drug Administration (FDA) approved the prostate specific 
antigen (PSA) test for monitoring disease status in prostate cancer patients 5. In 1994 the FDA 
approved the PSA test for early detection of prostate cancer in men of age 50 or older. PSA is a 
protein produced by cells in the prostate gland 6. The PSA test measures the level of the PSA 
protein in the blood to determine those at risk for developing the disease. Low levels of PSA are 
normal while increased levels of PSA can be present for benign or malignant conditions. 
However, PSA levels alone cannot effectively diagnose prostate cancer, therefore a digital rectal 
exam (DRE) is used in combination with PSA monitoring for diagnosing the disease. A multi-
institute funded clinical trial comparing the PSA test and DRE as screening tools determined that 
PSA testing alone identified 75% of tumors while DRE only identified 55%7. The combination 
of both the PSA test and DRE test identified the most tumors, 78%.   
 Figure 1-3 depicts the trend in prostate cancer detection from 1975 to 2008 according to 
the data provided from the National Cancer Institute Surveillance Epidemiology and End Results 
database. In 1975, 94 out of every 100,000 men were diagnosed with prostate cancer 3. 
Beginning in 1987, exponential growth was seen in the incidence rate, peaking in 1992 with 237 
out of every 100,000 men being diagnosed. As of 2008, 153 out of every 100,000 men were 
diagnosed. Several schools of thought have emerged as to the enormous spike in prostate cancer 
detection in the late 80’s early 90’s, with the introduction of PSA testing being on the forefront.  
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Figure 1-3: Prostate cancer incidence trend 1975-2008.  
In 1975, 94 out of every 100,000 men were being diagnosed with prostate cancer. Beginning in 
1987, exponential growth was seen in the incidence rate, peaking in 1992 with 237 out of every 
100,000 men being diagnosed. As of 2008, 153 out of every 100,000 men are being diagnosed 3. 
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Figure 1-3: Prostate cancer incidence trend 1975-2008.  
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Increased awareness of the disease as well as the fact that the average life span of Americans has 
increased are also contributing to the increase in detection of prostate cancer. 
The genetics of prostate tumorigenesis:  
 As stated before, genetics and family history can play a major role in the development of 
prostate cancer. Prostate cancer has a heterogeneous nature and is highly complex therefore 
mutations in a multitude of genes can play a role in tumor progression 8. Consequently, scientists 
are actively trying to identify genes, RNAs and proteins that can be associated with tumor 
progression and serve potentially as biomarkers. A biomarker is a biological molecule that can 
be quantified and is associated with normal or better yet abnormal forms of a disease. Table 1-1 
shows a list of genes and their associated functions from a recent study identifying differentially-
regulated genes from androgen-dependent to androgen-independent tumor progression 8. Only 
the most differentially expressed genes were selected; however, these are unquestionably not the 
only genes associated with prostate tumorigenesis. Genes are thought to influence tumor 
progression by the accumulation of point mutations that inadvertently inactivate the gene or by 
dysregulation via several routes.  
Tumor reoccurrence emerges in 15-30% of prostate cancer patients generally within 5 
years of initial treatment 2. These patients are then treated with androgen withdraw (AW) therapy 
and 70-80% of patients respond positively to this treatment temporarily. However, eventually the 
tumors progress to an  androgen-independent, a highly metastatic and aggressive form 9. In a 
normal prostate cell and androgen-dependent prostate tumors, testosterone will bind to the 
androgen receptor triggering the production of androgen transcripts which stimulates cell growth.  
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Table 1-1: Differentially expressed genes from androgen-dependent to androgen-
independent prostate tumor progression.  
Gene Symbol Gene Name Function Chromosome location 
IGF1 Insulin-like growth 
factor 1 
Involved in mediating growth and 
development 
12q23.2 
EGFR/ERBB Epidermal growth 
factor receptor 
Influences cell proliferation  7p12 
TM4SF1 Transmembrane 4 
L six family 
member 1 
Plays a role in regulation of cell 
development, activation, growth 
and motility. 
3q21-q25 
WT1 Wilms tumor 1 Plays essential role in normal 
development of urogenital system 
11p13 
PAGE-1 P antigen family 
member 1  
Expressed in a variety of tumors 
but not normal tissue. Function 
currently unknown 
Xp11.23 
RAB27B RAS related 
protein 27 B 
Member of the RAS oncogene 
family. Involved in vesicular 
fusion and trafficking 
18q21.2 
SOX4 SRY- sex 
determining region 
Y 
Regulates embryonic 
development. May function in 
apoptosis as well as tumorigenesis 
6p22.3 
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A study has shown that in cases of androgen-independent tumorigenesis, 50% of the tumors had 
point mutations in the androgen receptor gene. Scientists are currently unsure of how androgen 
receptors still promote cell growth in the absence of testosterone, but the point mutations may 
play a role in this phenomenon. 
Fairly recently small non-coding RNAs have been discovered to influence gene 
expression by either inhibiting translation or signaling the transcribed genetic message 
(messengerRNA, mRNA) for degradation. One class of responsible small RNAs are known as 
microRNAs (miRNAs, miRs).  
The discovery of miRNAs and their role in oncogenesis: 
 MicroRNAs are small non-coding RNAs that are 19-25 (nt) in length 10. They have the 
ability to post-transcriptionally regulate gene function by inhibiting translation or marking an 
mRNA for degradation. miRNAs have been shown to influence a variety of biological processes 
such as cell cycle regulation, differentiation, development, metabolism and aging 
10
. miRNAs 
were discovered in 1993 in C. elegan development
10
. They are highly conserved among 
organisms that are very distantly related such as invertebrates, vertebrates and plants. The 
miRBase database, a database of published miRNAs with annotations, listed 18,226 identified 
miRNAs from an assortment of organisms as of November 2011 11.  
 miRNAs presumably play a role in cancer due to their natural influence on cell cycle 
regulation (cell proliferation and apoptosis), differentiation, development and other related 
biological processes 12, 13. miRNAs are very frequently located in cancer-related genomic regions 
such as minimal regions of amplification, loss of heterozygosity, fragile sites, and common break 
point regions on or near oncogenes or tumor suppressor genes. miRNAs function as either 
 
 
13 
 
oncogenes or tumor suppressors. Oncogenes have been shown to be consistently up-regulated in 
tumor verses normal tissue whereas tumor suppressors are down-regulated in tumor versus 
normal tissue 10, 12. It also has been show that in some instances, a miRNA may act as a tumor 
suppressor in one setting and an oncogene in another 12. Studies have shown that in some 
cancers, a global deregulation of miRNAs has been found. This implicates that miRNAs 
generally target genes associated with biological processes that are critical for development or 
progression of the disease.   
MicroRNA biogenesis and mRNA targeting: 
 miRNAs have been located in the genome in both introns and exons of coding proteins as 
well as intergenic regions 12. It is quite common for them to be found polycistronically, clustered 
in groups of 2-7 miRNAs as a single transcript controlled by a common regulator, or 
monocistronically 12, 14. The first step of miRNA biogenesis begins in the nucleus where the 
precursor is transcribed by RNA polymerase II, adding a 5’ cap and a 3’ poly-A tail (Figure 1-
4)10, 12-14. This pri-miRNA is then cleaved into a 70-100 nt hairpin shaped fragment by a 
ribonuclease II called Drosha and the double-stranded DNA binding protein DGCR8. The new 
fragment is referred to as pre-miRNA. After the hairpin structure is formed, the pre-miRNA is 
exported out into the cytoplasm by means of the nuclear export factor exportin. The pre-miRNA 
is then processed into a 19-25 nt miRNA duplex via association with the ribonuclease III Dicer. 
The miRNA is then incorporated into the RNA-induced silencing complex (RISC). The miRNA 
is now mature and is guided toward its intended mRNA target.  
 miRNAs target genes via complementarity between the miRNA sequence (”seed” region, 
bases 2-7 of the miRNA from the 5’ end) and the 3’UTR sequence of the mRNA transcript 12, 14.  
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Figure 1-4: microRNA Biogenesis 
1. Within the nucleus, the precursor is transcribed by RNA polymerase II and the 5’cap and 
3’poly-A tail is added.  
2. Also within the nucleus, the pri-miRNA is cleaved into a 70-100 nt hairpin shaped 
fragment known as pre-miRNA by Drosha.  
3. The pre-miRNA is exported out of the nucleus into the cytoplasm by Exportin.  
4. Now in the cytoplasm, the pre-miRNA is processed into a 19-25 nt miRNA duplex by 
Dicer.  
5. The miRNA duplex is incorporated into RISC and one strand selected as the mature 
miRNA and is now prepared to locate its intended target.    
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Figure 1-4: Steps in microRNA Biogenesis 
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Recently it has been shown that in some cases, a miRNA’s seed sequence complementarity will 
correspond to the 5’UTR of an mRNA transcript or potentially, association with any portion of 
the target mRNA is sufficient for translational repression 15. Perfect or near perfect binding 
complementarity of the miRNA seed region to the target gene leads to mRNA degradation 
through the RNA-mediated degradation pathway. Imperfect complementarity is thought to lead 
to translational repression 12 at some step down stream of initiation but the mechanism for this 
effect remains to be validated 15. It is estimated that over 30% of protein coding genes are 
regulated by miRNAs 12. This along with the fact that the seed region of most miRNAs is around 
6 nt in length, it is suggested that miRNAs can regulate multiple protein-coding genes.  
The Oncogenic Potential of miR17-3p and miR125b when differentially expressed: 
 The gene that encodes for the miR17-3p (miR17*) mature miRNA is located on 
chromosome 13 in a polycistronic cluster known as the miR-17-92 cluster 16. The cluster is 
transcribed into a primary transcript that encodes six miRNAs 17. These include miR17 (miR17-
5p and miR17-3p mature miRNAs), miR18a, miR19a, miR20a, miR19b-1 and miR92-1. The 
cluster has been shown to be activated by the c-MYC transcription factor 18.  In human solid 
tumors, miR17-5p was shown to be up-regulated in breast, colon, lung, pancreas and prostate 
cancers 
19
. In the same study, miR20a was shown to be up-regulated in colon, pancreas and 
prostate cancers. miR17-3p has been shown to be down-regulated in prostate cancer when 
comparing benign versus malignant tumor samples collected via laser capture microdissection 19.  
A gene that encodes for the miR125b is located in two separate locations within the 
human genome, chromosomes 11 and 21 (precursor miR125b_1 and miR125b_2 respectively) 
both found monocistronically. When fully processed both precursors produce mature miR125b 
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molecule. miR125b has been shown to be differentially dysregulated in a multitude of human 
cancers: down-regulated in breast 20, 21, ovarian 22, squamous cell carcinoma 23, but up-regulated 
in neuroblastoma 24, stomach 25, colon 21, and bladder 26. According to miRecords, an online 
database of miRNA-target interactions, miR125b has been experimentally proven to target 52 
proteins as of November 201027.  
Prostate Cancer Cell Models: 
 There are three classical sets of tissue culture cell lines used by researchers to help better 
investigate prostate cancer overall and prostate cancer tumor progression. The LNCaP, DU-145, 
and the P-C3 cell lines 28. The DU-145 cell line was the first prostate cancer cell line to be 
established and was derived from a metastatic tumor excised from the brain of a 69 year old 
white male with prostate cancer. These cells fail to express the androgen receptor gene/protein 
(AR), therefore classifying them as androgen-independent.  
 The LNCaP cell line was derived from a biopsy of a lymph node metastasis from a 50 
year old white male with prostate cancer 28. Although there are 60+ LNCaP sublines, the parental 
cell line expresses both the AR gene and protein, classifying them as androgen-dependent. This 
is currently the most popular cell line used by researchers.  
 The PC-3 cell line was derived from a lumbar vertebra metastasis from a 62 year old 
white male with prostate cancer 28. The parental cell line fails to express the AR gene/protein, 
classifying them as androgen-independent. There are 11 sublines that have been derived from the 
PC-3 parental cell line, some of which are androgen-dependent.   
 The model system used in our lab is a genetically related androgen-independent cell line 
derived from a non-neoplastic prostate epithelial cell from a 63 year old African American male 
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29. These cells were immortalized with the SV40 Large T Antigen gene and referred to as P69.  
The P69 cell line is non-metastatic, and weakly tumorigenic. The M12 cell line was derived from 
the parental P69 line by interperitonal injection into male, athymic nude mice.  In some cases 
after sufficient time (months) tumors developed.  Tumors were collected, cells dispersed, and 
reinjected into mice as before 29.  After three rounds of injections the resulting M12 cell line was 
derived. The karyotype for the M12 subline shows an unequal translocation of chromosome 
16:19, resulting in the loss of most of one copy of chromosome 19.  Interestingly, an 
independently derived second cell line showed a similar chromosomal rearrangement as the M12 
cell line suggesting this chromosomal rearrangement can be independently duplicated during 
tumorigenesis. The M12 cell line is highly metastatic and tumorigenic when injected 
orthtopically into male, athymic nude mice. The F6 subline was derived from the M12 cell line 
by restoration of the lost copy of chromosome 19 via micro-cell fusion techniques 30. The 
restoration of the second copy of chromosome19 resulted in a poorly tumorigenic, non-
metastatic phenotype for the F6 cell line, like the P69 predecessor. Altogether, these cell lines 
generate a useful model system for studying factors that contribute to the progression from a 
normal epithelial cell line to a highly metastatic, tumorigenic versus weakly variant, originally 
derived from a common cellular background.   
 Previously, it was found that the P69 cell line had a relatively high abundance of the 
human miRNA 17-3p. The M12 subline exhibits a two-fold decrease in the expression of miR17-
3p compared to the parental P69 cell line.  A M12 subline with restored expression (approximate 
an additional 3-fold) of miR17-3p (M12+miR17-3p) was derived 31. A variety of experiments 
suggests that miR17-3p acts as tumor suppressor in vitro and in vivo 
31
.  
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The ErbB Protein family and it’s role in oncogenesis: 
 The the ErbB family or epidermal growth factor receptor (EGFR) family is comprised of 
four protein homologs: EGFR/ErbB1/HER1, ErbB2/HER2/Neu, ErbB3/HER3 and ErbB4/HER4 
32. All of these members are type 1 transmembrane tyrosine kinase receptors and contain a 
extracellular ligand-binding domain, a single transmembrane-spanning region and a cytoplasmic 
protein tyrosine kinase domain attached to a C-terminal tail 2. Signaling by the ErbB family has 
been shown to regulate several cellular activities including cell division, migration, adhesion, 
differentiation and apoptosis.  
The ErbB receptors are activated by mesenchymal ligands to include heregulines, 
neureguins and other EGF-like ligands, each with an EGF-like domain for binding specificity 32. 
When a ligand binds to the extracellular ligand-binding domain, it activates the ErbB receptor 
allowing dimerization to another ligand-bound ErbB receptor2. This is true for all members 
except for ErbB2 which is constitutively available for dimerization, thus not requiring ligand 
binding for activation 32.  
  The ErbB receptors can either homo or hetero dimerize and this action is essential to 
their function and signaling activity 2. Homodimers only propagate a weak signal compared to 
heterodimers. ErbB2 has been shown to be the primary heterodimerization partner for all other 
ErbB members 32 and ErbB2 heterodimers are the most potent 2. ErbB3 is unable to 
homodimerize due to insufficient kinase signaling but ErbB2-ErbB3 heterodimers are the most 
mitogenic of all of the other heterodimer combinations. ErbB4 expression has been shown to be 
lost in prostate cancer 33. 
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Once dimerization has occurred, the kinase domain is activated and autophosphorylation 
of the tyrosine residues within the cytoplasmic tail follows 2. The signaling cascade is initiated 
when docking of an adapter protein occurs at the phosphotyrosine residues. Each of the ErbB 
receptors has a unique pattern of  tyrosine residues phosphorylated in the C-terminal tail, 
specifying which adapter proteins may bind and in turn, which signaling pathways are initiated 
32. ErbB3 comprises six binding sites for the p58 regulatory subunit of the PI3Kprotein 
(phosphoinositide 3-kinase), enabling direct activation of the PI3K signaling pathway 2, 32. All 
members of the ErbB family have binding sites for activators of the MAPK (mitogen activated 
protein kinase) pathway as well. 
Activation of the PI3K pathway involves initial EGFR dimer binding with a PI3K adapter 
protein, activating downstream AKT which in turn inhibits the FOXO transcription factors, 
mediators of apoptosis 34. Activation of the MAPK pathway involves initial binding with a 
MAPK adapter protein, activating downstream RAS, RAF and MEK which activates 
downstream MAPK, activating the ELK transcription factor which promotes transcription and 
cell growth. Gioeli et al measured 82 primary and metastatic prostate tumor samples and showed 
increasing MAPK activation correlated with increasing Gleason score and tumor stage 35. These 
are only two examples of major signaling pathways activated by the EGFR family. 
Three main causes of the ErbBs being involved in oncogenesis have been described: 1) 
increased receptor expression and/or gene amplification, 2) increased ligand expression,  and  3) 
mutations causing constitutive activation of the receptor 2. Abnormal activity has been linked 
more to the increased expression of the ligand than mutations in the receptor. ErbB2 
overexpression has been associated with metastsis to the bone in both breast and prostate cancer 
36. Overexpression of the ErbB2 and ErbB3 heterodimer has been associated with increased 
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tumor growth in breast cancer via the PI3K pathway and is thought to promote the metastatic 
potential of the disease 37. Chen et al performed a study using prostate cancer samples that were 
both androgen –dependent and –independent, and concluded that there was a statistically 
significant increase in ErbB3 expression from androgen –dependent to –independent tumor 
samples 38. These findings attest to a significant role for ErbB2 and ErbB3 in prostate 
tumorgenesis.  
Inhibitors of the ErbB protein family have been developed and are now used clinically to 
treat breast cancer resulting in decreased ErbB2 activity 2. However, no inhibitor developed 
against ErbB2 has been effective in clinical trials against prostate cancer. Thus far, inhibitors of 
ErbB3 have only been mildly considered, since ErbB2 was thought to be the key player in cancer 
development. Table 1-2 lists ErbB family members with miRNAs proven to target the ErbBs, 
and cancer in which the interactions have been identified 27. Knowing that miRNAs function as 
molecules that either inhibit translation or initiate degredation of their target mRNA, they are 
interesting as potential biomarkers of the disease or as a possible alternative to drug therapy 39. 
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Table 1-2: ErbB family members expressed in cancer with proven miRNA interactions.  
Protein target Proven miRNA  Cancer 
ErbB1 hsa-miR-7 Lung, Breast, Glioblastoma 
ErbB2 hsa-miR-125a Breast 
 hsa-miR-125b Breast 
 hsa-miR-331-3p Prostate 
 hsa-miR-548d-3p Cervical  
 hsa-miR-559 Cervical 
ErbB3 hsa-miR-125a Breast 
 hsa-miR-125b Breast 
 hsa-miR-205 Breast 
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Objectives: 
 Interest in miRNAs has increased over the last years due to their potential as both 
biomarkers of disease as well as alternatives to drug therapy. Identification of miRNA targets as 
well as their contribution to the development of disease has moved to the forefront of cancer 
research. Traditionally used gene arrays evaluate levels of gene expression and are unable to 
capture the true nature of protein expression due to post-transcriptional regulation via miRNAs. 
Furthermore, strictly computational approaches have generated only minor success in identifying 
crucial miRNA targets due to the many possible conformations of miRNA/target coupling.  
Our objective is to take a novel approach. Here, a high throughput proteomics method 
combined with a computationally derived network is used to identify key proteins driving 
prostate cancer progression. This approach enables the evaluation of gene expression levels post-
transcriptionally in cancer cell lines with key protein node predictions to identify potential 
miRNA interactions. This analysis coupled with screening of the miRnome (miRNA 
transcriptome) should enhance the identification of relevant miRNAs dysregulated in prostate 
cancer which contribute to tumor progression.  Additional experiments such as single miR 
analysis in model prostate cancer cell lines compared to human tumors will further validate the 
conclusions from this multifaceted approach. 
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Chapter 2: A Proteomics Approach to identifying Key Proteins dysregulated in Prostate 
Cancer. 
Proteomics and RPMA Technology: 
 Traditionally, gene arrays have been used to try to predict genes involved in prostate 
cancer development as well as identify stages of tumor progression 40. Yet the mechanism behind 
using gene arrays is to reverse transcribe mRNA into cDNA. Therefore gene expression arrays 
measure mRNA levels present  prior to translation. Since miRNAs regulate levels of gene 
products driving translation, measuring the actual level of protein products should be a more 
accurate method of measuring a gene/protein’s activity and potential influence in the cell.  
 Two major types of protein arrays are in use: Forward phase protein microarrays and 
Reverse Phase Protein Microarrays (RPMA) 41. Generally, in forward phase protein arrays, the 
antibody(s) of the protein(s) of interest are spotted on to a glass or silica chip used as a bait 
molecule, and the chip is incubated with the protein lysate of interest 42. Using this method, only 
one type of sample condition can be measured at a time. Conversely, in RPMAs, the cellular 
lysate is spotted onto the chip in a series of dilutions and the chip is incubated with the antibody 
to the protein of interest 43. This miniature dilution curve is designed to insure accurate 
quantification and to describe the overall dynamic range of protein detection. This method allows 
for multiple samples to be spotted on the same chip, but requiring one slide for each antibody 
analyzed. Overall, both methods produce a high-throughput system for measuring expression 
levels of hundreds of proteins across multiple sample conditions.  
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Compared to conventional western blotting methods to measure protein expression, 
protein microarrays are undoubtedly more efficient considering sample size and time 
consumption 44. Western blots use on average around 30ug of protein lysate per sample, 
depending on how abundant the protein of interest is in the specific cell or tissue-type. Protein 
microarrays can use picograms to femtograms of protein lysate, using only 200 cells total to print 
one array slide. Anywhere from 5,000 to 20,000 total cells is sufficient to measure protein 
expression across 100 different proteins of interest.  
Tissue Culture Methods: 
 The ‘stock’ media used for P69 and M12 cell lines includes: RPMI 1640 media with L-
glutamine from Sigma-Aldrich, 5% fetal bovine serum, ITS (5µg/ml insulin ‘I’, 5µg/ml 
transferrin ‘T’ and 5ng/ml selenium ‘S’) from Collaborative Research in Bedford, MA and 
0.05mg/ml gentamycin to prevent bacterial growth contamination. The M12+miR-17-3p cell line 
contains a stably integrated plasmid and requires puromycin (100µg/µl) in addition to the ‘stock’ 
media for selection.  
All cell types were grown at 37◦C in 250ml T75 flasks and were split when confluent. 
Cells were harvested from the flask via scraping over ice and using cold 1xPBS. Cells were 
pelleted at 1000 rpm in a 15ml conical tube, re-suspended in 1xPBS and pelleted a second time 
at 5000 rpm in a 1.5ml eppendorf tube. The cell pellets were flash frozen using liquid nitrogen 
and stored at -80◦C.  
For the purpose of this experiment, 1 cell pellet was made from each flask and 3 
consecutive passages (denoted as ‘T’ numbers) of each cell line were harvested. The cell pellets 
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were then sent on dry ice to Dr. Emanuel Petricoin III’s lab at George Mason University’s Center 
for Applied Proteomics and Molecular Medicine.  
Reverse Phase Protein Microarray performed at George Mason University: 
 The cells were lysed prior to spotting in buffer containing 9M urea, 4% 3-[(3-
chlamidopropyl) dimethylammonio]-1-propanesulfonate, 2% pH 8.0-10.5 Pharmalyte, and 
65mM DTT. Each cell pellet lysate was spotted in a miniature serial dilution curve (neat, 1:2, 
1:4, 1:8, 1:16 and buffer) onto a glass nitrocellulose-coated slide. The RPMA protocol as 
previously described was followed 45. Overall, antibodies for 111 different proteins were 
incubated with our various cell lysates to follow protein expression in our prostate cancer 
progression model. Many of the antibodies were monoclonals’ raised against specific 
phosphorylated residues of the host antigen; thus, used to measure differences in activating 
various signaling pathways deemed important in cancer. After verification of their internal 
standards and normalization, the Petricoin lab returned the proteomics results for statistical 
analysis.  
Statistical Analysis of the RPMA data: 
 Microsoft Excel was used to perform a two-sample equal variance T-Test to compare the 
protein expression data across the different cell lines provided. A strict probability value (p-
value) of p <= 0.001 was used to correct for variation among multiple samples and to identify 
truly significant changes. Those with significant changes were converted into fold changes by 
dividing the average expression of the protein in one cell line by the average expression of the 
protein in the comparison cell line. Figure 2-1 depicts the overall process of the statistical 
analysis using protein ErbB2 as an example.  
 
 
27 
 
Figure 2-1: Overview of the Statistical Analysis of the RPMA data.  
A T-Test was performed to compare the protein expression data across the different cell lines 
provided. A p-value of p <= 0.001 was used to correct for multiple samples and to identify truly 
significant changes. Those with significant changes were converted into fold changes by dividing 
the average expression of the protein in one cell line by the average expression of the protein in 
the comparison cell line. 
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Figure 2-1: Overview of the Statistical Analysis of the RPMA data. 
   
 
 
 
 
P69 
ErbB3 
T23- 6173.37 
T24- 7186.79 
T25- 8192.71 
M12 
ErbB3 
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T16- 14647.13 
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p <= 0.001 
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RPMA Findings: 
 Table 2-1 is an overview of proteins shown to have statistically significant changes in 
expression level (p-value <= 0.001) within our prostate cancer progression model as measured 
by RPMA. Phosphorylated c-KIT, ErbB3 and ErbB2 were the most interesting of the proteins 
changing in our proteomics data, because for the most part they showed significant changes 
across multiple cell lines. All three proteins showed an increase in expression from the non-
tumorigenic P69 cell line to the highly metastatic, tumorigenic M12 subline except there was no 
significant change (NS) in the phosphorylation status of ErbB2 (phosphorylated Tyrosine 1248).  
Interestingly, a decrease in expression from the M12 cell line to the weakly tumorigenic, non-
metastatic M12+miR-17-3p subline with increased expression of the tumor suppressor miR17-3p 
was apparent except for ErbB2.   
These results are consistent with a protein that is being dysregulated by increased 
expression in the highly metastatic cell line compared to the non-tumorigenic/poorly tumorigenic 
variant in our model of disease. Since miR17-3p is dysregulated in the opposite direction in our 
progression model, (decreasing from P69 to M12 and then increasing from M12 to M12+miR-
17-3p), there is a possibility that miR-17-3p may be directly targeting pc-KIT, ErbB3 mRNAs 
and possibly ErbB2/pErbB2 due to significant changes in at least one direction. Confirmation of 
direct miRNA/target interactions is imperative in theidentification of possible biomarkers as well 
as therapeutic options for disease. This hypothesis warrants further testing. 
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Table 2-1: Fold changes of proteins with statistically significant expression changes based 
on RPMA. 
Protein P69       M12 fold change M12       M12+miR-17-3p fold change 
*pc-KIT 1.7x10
7
X ↑ 1.7x107X ↓ 
ErbB3 2X ↑ 1.3X ↓ 
ErbB2 1.7X ↑ NS 
*pErbB2 NS 1.6X ↓ 
*pERK 5.1X ↓ NS 
*pJak1 NS 1.9X ↓ 
NS- No significant change 
↑ Increase in expression 
↓ Decrease in expression 
*p = antibody used specific to a phosphorylated residue 
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Chapeter 3: A Networks Approach to Identifying Important miRNA Regulated Proteins in 
Prostate Cancer 
Networks Biology: 
 The human body, organs, cells are all very complex systems that require intricate 
coordination and proper execution of a remarkable number of biological processes in order to 
perform properly 46. Thus far, 5 main types of biological networks have been characterized to 
help better understand these biological processes and to observe how the smaller pieces create 
the whole. These networks include transcription factor-binding, phosphorylation, metabolic, 
genetic, and protein-protein interaction. Focusing on protein-protein interaction networks, the 
proteins are considered nodes, and interactions between the nodes are represented as edges. The 
interaction of proteins with other proteins in the cell plays a key role in most biological processes 
47. The evaluation and identification of all protein-protein interactions within the cell is thought 
to be the key to uncovering how cells function on a large-scale, under normal and disease 
conditions.     
Building a protein-protein interation network of proven targets of miRNAs shown to be 
dysregulated in the Prostate: 
 Figure 3-1 depicts the process of building the protein-protein interaction network 
of proven targets of miRNAs dysregulated in the prostate. A list of 111 dysregulated miRNAs, 
associated with the development of prostate cancer was obtained from the miR2Disease online 
resource 48. The database was interrogated using the included html search function using the 
query term “prostate carcinoma”. Causal and unspecified relationships were included. A PERL 
script was written to extract each miRNAs expression pattern and literature reference.  
 
 
32 
 
Figure 3-1: Overview of building a protein-protein interaction network of proven targets of 
miRNAs dysregulated in the prostate.  
 miRNAs dysregulated in the prostate were obtained from the miR2Disease database 48. 
Experimentally proven miRNA/target interactions were obtained from joining the information in 
the Tarbase and miRecords repositories 27, 49. Prostate transcriptome profiles were obtained from 
Unigene to determine transcripts expressed in the prostate 50. Agilent and Cytoscape were used in 
conjunction to build the protein-protein interaction networks. The network properties were 
calculated using CentiScaPe 51-53 . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
33 
 
Figure 3-1: Overview of building a protein-protein interaction network of proven targets of 
miRNAs dysregulated in the prostate. 
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A table of all known miRNA/gene interactions was assembled by combining the 
information in Tarbase and miRecords, repositories of experimentally supported miRNA target 
interactions that were downloaded in May of 201127, 49. A PERL script was written to compile the 
data extracted from both repositories to create a single non-redundant list. Using the 
miR2Disease list of miRNAs dysregulated in the prostate, a comprehensive list of validated 
targets associated with these miRNAs was created 48. 
 Transcriptome profiles for the prostate gland were obtained from the Unigene database 50. 
A prostate specific protein-protein interaction network was built. A PERL script was used to 
extract identifiers of transcripts that showed any level of expression in the prostate gland, the 
identifiers were then converted to HUGO gene symbols. There were a total of 608 confirmed 
proteins identified that are reported targets of miRNAs dysregulated in the prostate. These were 
obtained by combining the comprehensive list of validated miRNA/target interactions and the list 
of transcripts expressed in the prostate.  
 Using Cytoscape 2.8 along with the Agilent literature search (v2.76) tool, two 
literature mined prostate protein-protein interaction networks were inferred 51, 52. For the first 
network, each protein in the list of 608 known prostate cancer miRNA target proteins was used 
as a search term in the Agilent literature search tool and the search was controlled to limited 
interactions to Homo sapiens with a maximum of 10 hits per search string/search engine. The 
second, random network, was built in the same manner using 608 randomly chosen proteins 
expressed in the prostate gland according to the Unigene database, disregarding known miRNA 
status50. Visualization was accomplished using Cytoscape and topological network descriptors 
were estimated using CentiScaPe 53. 
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The random network built was shuffled 50,000 times using a degree preserving edge 
shuffle random network plugin developed by engineers at Syracuse University and implemented 
in Cytoscape. The plugin was downloaded 
(http://sites.google.com/site/randomnetworkplugin/Home) as a .jar file and installed in the 
Cytoscape package. 
Statistical analysis of the Networks: 
Differences in network distributions were evaluated using an Analysis of Variance test 
(ANOVA) with significance set at probability <= 0.05. All statistical analyses were performed 
using JMP 8.0 (Statistical Analysis Software Cary, NC). The distribution of node degree for the 
prostate miRNA targeted network and the random network were created using the R Project for 
Statistical Computing (http://www.r-project.org/).  
Network Findings:  
 In networks analysis, node degree can be used to surmise the proteins contribution to the 
stability of the network/cell. Node degree represents the maximum interaction potential of a 
protein. A random protein-protein interaction network of proteins was compared to the results 
obtained from the miRNA/proven target network and determine the likelihood that the 
interaction would have been seen due to chance alone. Table 3-1 shows the node degree 
distribution differences between the random network of proteins expressed in the prostate 
compared to the miRNA/proven target network of proteins 54. The analysis shows that there is an 
enrichment of more highly connected nodes in the miRNA/proven target network than the 
network of randomly chosen proteins expressed in the prostate. The random network had an 
average node degree of 5 opposed to the miRNA/target networks average node degree of 30. 
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Table 3-1: A comparison of node distributions between the random network of proteins 
expressed in the prostate and the miRNA/proven target Prostate Cancer network. 
Network Mean Node 
Degree 
Standard 
Deviation 
Minimum Maximum 
Prostate Cancer miRNA target protein 29.80 47.47 1 290 
Random prostate protein 4.46 4.24 1 28 
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The high average node degree implies that miRNAs preferentially target transcripts that 
impact a large number of proteins in the cell. The miRNA/proven target network had a maximum 
node degree of 290 compared to the random network which had a maximum node degree of 28. 
It has been shown that molecules with higher node degrees are more essential to cell growth and 
function 55. Perturbations of such highly connected nodes have an increased likelihood of 
negatively impacting the stability of the network/cell 46, leading to a variety of diseases such as 
cancer 56.   
The 608 proteins proven to interact with miRNAs dysregulated in the prostate were 
ranked based on their node degree. ERBB2 and ERBB3, both members of the epidermal growth 
factor receptor (EGFR) family, were found to be differentially expressed at a statistically 
significant level across P69, M12, and M12+miR17-3p cell lines in our proteomics analysis. 
Table 3-2 depicts the results of the EGFR protein family represented in the protein-protein 
interaction network of proven target/miRNA interactions 54. The EGFR family was found to be 
the 6
th
 highest ranked node in our miRNA target network. The higher node degree infers the 
importance of this protein family to the stability of the cell/network.   
Perturbation of the EGFR family within the cell, potentially by a miRNA, could prove 
detrimental to the stability and health of the cell. ErbB2 and ErbB3 show a significant increase in 
expression between the non-tumorigenic P69 cell line and the highly tumorigenic, highly 
metastatic M12 subline, as well as a high node degree of 248 in our miRNA/target network. 
From these results, we believe that ErbB2 and ErbB3 have the potential to play a key role in the 
development of prostate cancer. However, the identification of the cause and consequences of 
the dysregulation of ErbB2 and ErbB3 is necessary to ultimately prove their role in disease.  
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Table 3-2: Protein node connectivity results for EGFR. 
Protein Node Degree Function Known miRNAs 
EGFR 248 Cell proliferation hsa-miR-7, hsa-miR-
125b, hsa-miR-125a, 
hsa-miR-331-3p, hsa-
miR-548d-3p, miR-
hsa-559, hsa-miR-205 
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Chapter 4: Identification of possible miRNA/ErbB2 or ErbB3 interactions. 
 
Screening of the miRnome: 
 qRT-PCR based microarrays have been developed to produce a high-throughput method 
of screening miRNA expression levels of all currently known miRNAs in order to identify key 
players in different diseases. Exiqon has developed the miRCURY LNA microRNA Arrays 
(catalog # 203607, miRNA human panel 1 and 2 V2.M) for screening of the miRnome 
(microRNA transcriptome) using two 384 well plates. Total RNA was extracted using the 
miRVana miRNA Isolation Kit from Invitrogen and 50ng of RNA from each cell type was 
converted to cDNA using the Exiqon miRCURY LNA Universal RT miRNA PCR kit. The ABI 
7900-HT Fast Real-Time PCR System from Applied Biosystems (ABI) was used to amplify and 
quantify the expression of 700 known miRNAs using recommended settings (95◦ C for 10 
minutes, followed by 40 cycles of 95◦ for 10 seconds and 60◦C for 1 minute).  
Utilizing GenEx software from Exiqon, Interplate calibration was performed to minimize 
interplate variation. The cycle threshold (CT) for each microRNA was then normalized to the 
global mean of the array plate (CT- mean CT). Undetectable expression levels were set greater 
than the highest normalized CT value observed for that particular cell line. The P69 cell line 
normalized expression value was used as the calibrator. Table 4-1 shows the miRNA that was the 
most differentially expressed in our prostate cancer progression model. Achieving a fold change 
of this magnitude is possible when the expression level of miR125b is very high in one cell line 
(P69) and very low in the comparison cell line (M12). miR125b was proven to target ERBB2 
and ERBB3 in breast cancer and CASP6, CASP7 and BAK1 in prostate cancer. Single miR  
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Table 4-1: Results of the most differentially expressed miRNA in our miR screen. 
miRNA P69        M12 Proven Targets Cancer 
miR125b 9055X ↓ ERBB2, ERBB3  
CASP7, CASP6,BAK1 
(50+ total) 
Breast 
Prostate 
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analysis is required to confirm the significance of miR125b dysregulation in our prostate 
progression model.   
Single miR analysis of miR125b: 
 Single miR analysis of miR125b expression in our prostate cancer progression model was 
performed to verify the results of the Exiqon miR screen. Total RNA was extracted as previously 
described in the above section. The TaqMan microRNA Assay Kit (Kit # 000449) from ABI was 
used to convert 20ng of RNA from P69 and M12 cells to cDNA, and subsequently analyzed in 
triplicate by qRT-PCR. TaqMan probes of RNU48 and miR125b were used in the qRT-PCR 
reaction using the ABI 7300 Real-Time PCR system with recommended settings (95◦ C for 10 
minutes, followed by 40 cycles of 98◦ for 15 seconds and 60◦C for 1 minute). Expression mean 
values were normalized to RNU48 and the P69 cell line was used as the calibrator. Figure 4-1 
depicts the relative level of miR125b expression in the M12 cell line compared to the P69 cell 
line. A 19.7-fold decrease in miR125b expression was observed from the P69 cell line to the 
M12 cell line.  
 To verify the dysregulation of miR125b in human prostate tissue, single miR analysis of 
miR125b expression in benign, stroma, prostatic intraepithelial neoplasia (PIN), benign prostatic 
hyperplasia (BPH) and tumor cells was performed. The patient sample was obtained from the 
Virginia Commonwealth University Anatomic Pathology Tissue Depository with approved IRB 
protocol. The protocol for laser-capture microdissection (LCM) of formalin-fixed paraffin-
embedded (FFPE) patient samples was followed as previously described by Zhang et al 31. Total 
RNA was extracted from benign, stroma, PIN, BPH and tumor tissue using the PicoPure RNA 
extraction kit from Life Technologies. RNA quantity and integrity were assessed using the  
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Figure 4-1: The relative level of miR125b expression in the M12 cell line compared to P69. 
Total RNA was extracted from M12 and P69 cell pellets, 20ng of each RNA extract was 
converted to cDNA and qRT-PCR was performed (in triplicate). Expression level means were 
normalized to RNU48 and the P69 normalized value was used as the calibrator. Standard 
deviation within each sample is shown. 
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Figure 4-1: The relative level of miR125b expression in the M12 cell line compared to P69. 
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Agilent Bioanalyzer. cDNA conversion and qRT-PCR was performed in triplicate using the 
TaqMan assay as previously described. The mean expression values of each sample were 
normalized to RNU48 and the benign normalized expression value was used to calibrate all 
samples.  
Figure 4-2 depicts the relative level of miR125b expression in stroma, PIN, BPH and 
tumor tissue compared to benign tissue expression. A 1-fold increase in miR125b expression was 
observed from benign to stroma tissue. A 2.75-fold decrease in expression was observed from 
benign to PIN tissue with a 2.82-fold decrease from benign to BPH tissue. A substantial 2452-
fold decrease in expression was observed from benign to tumor tissue.  
Although only one individual human sample was tested, the result of the single miR 
analysis of miR125b expression in human tissue was consistent with the single miR data and 
miR screen analysis of our prostate cancer progression model. miR125b expression was 
significantly lower in the highly metastatic, highly tumorigenic M12 cell line within both the 
miR screen and individual miR analysis compared to the non-tumorigenic P69 cell line. Also, 
miR125b expression was significantly lower in human tumor tissue compared to benign tissue.  
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Figure 4-2: The relative level of miR125b expression in stroma, PIN, BPH and tumor tissue 
compared to benign tissue of one individual human prostate sample.  
LCM of FFPE tissue was performed. Total RNA was extracted and was converted to cDNA. 
qRT-PCR was performed and the expression means were normalized to RNU48. Expression 
values of all tissues were calibrated to normalized benign tissue expression. Standard deviation 
within each sample is shown. 
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Figure 4-2: The relative level of miR125b expression in stroma, PIN, BPH and tumor tissue 
compared to benign tissue of one individual human prostate sample.  
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The potential for miR125 to target ErbB2 or ErbB3:  
 Our computational networks approach to identify key proteins that are influenced by 
miRNAs dysregulated in prostate cancer suggested the ErbB family of proteins. These proteins 
are highly connected nodes in the prostate cancer network suggesting that they are key players in 
the development/progression of prostate cancer. Additionally, our proteomics analysis of the 
prostate cancer progression model showed that ErbB2 and ErbB3 are significantly dysregulated 
between P69 -> M12.Overall the results from analyzing the miRnome of our prostate cancer 
progression model, verified by single miRNA analysis, identified miR125b as being the most 
differentially expressed tumor suppressing miRNA in our cell lines. Scott et al proposed that 
miR-125b binds directly to position 19-44 within the 3’ UTR of ErbB2 (5’-
GCAGAAGCCCUGAUGUGUCCUCAGGGA-3’) and position 8-26 of ErbB3 (5’-
UCCCUGUGGCACUCAGGGA-3’) controlling metastatic potential of breast cancer cells 20. 
Based on the reported results, it is reasonable to postulate that miR125b could be directly 
targeting ErbB2 and ErbB3 in prostate cancer via the binding sites described above. 
Computational analysis of ErbB2 and ErbB3 3’UTRs and miR125b: 
 The 3’UTR sequences for ErbB2 and ErbB3 were obtained from the National Center for 
Biotechnology Information (NCBI) and the sequence for miR125b was obtained from miRBase 
27, 57, 58. The miR125b sequence and 3’UTR sequences of ErbB2 and ErbB3 were submitted to 
RNAhybrid, a miRNA/RNA minimum free energy structural hybridization prediction tool, using 
the default settings 59. Figure 4-1 depicts the predicted structural interaction of miR125b and the 
3’UTRs of ErbB2/ErbB3. Many of the proven miRNA binding sites have perfect seed region 
(bases 2-8) Watson-Crick binding, adequate minimum free energy of formation (deltaG < -20.0  
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Figure 4-1: Previously described miR125b coupling with the 3’UTR of ErbB2 or ErbB3. 
The sequences of the complete 3’UTR of (A) ErbB2/ (B) ErbB3 and the sequence of miR-125b 
were compared using RNAhybrid to predict potential interactions of miR-125b (green) with the 
3’ UTRs of ErbB2/ ErbB3 (red) 59. Potential structures and the minimum free energy of 
formation of the binding sites proposed by Scott et al are shown.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
49 
 
Figure 4-1: Previously described miR125b coupling with the ErbB2 or ErbB3 3’UTRs. 
A.  
B.  
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kcal/mol), and some degree of 3’ stabilization. The structure of the proposed binding sites for 
both proposed miRNAs adhere to previously observed characteristics and thus it is reasonable to 
suspect that these interactions would occur in vivo.  
Mutation of seed region binding in the 3’UTRs of ErbB2 and ErbB3 is required to 
determine if these are true miRNA/target interactions within the prostate gland and if these 
interactions may be contributing to the development of prostate cancer. In order to evaluate 
potential binding, a reporter construct containing mutations of three bases (2-4, GGG to TTT) 
within the 3’UTRregion of ErbB2 and ErbB3 proposed to be under miR-125b regulation was 
constructed.  To confirm that the mutations decrease the likelihood of microRNA regulation, the 
mutated sequence was evaluated using RNAhybrid. Since complete seed region binding does not 
exist, there is a poor minimum free energy. Most likely neither the mutant ErbB2 3’UTR or the 
mutant ErbB3 3’UTR are likely to be under the control of miR-125b regulation (Figure 4-2).  
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Figure 4-2: miR125b coupling with the mutated ErbB2 and ErbB3 3’UTRs. 
The sequences of the proposed mutant 3’ UTR of (A)ErbB2 / (B)ErbB3 and the sequence of 
miR-125b were compared using RNAhybrid to predict potential interactions of miR-125b 
(green) 59. Potential structures and the minimum free energy of formation of the mutant binding 
sites are shown.  
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Figure 4-2: miR125b coupling with the mutated ErbB2 and ErbB3 3’UTRs. 
A.  
B.  
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ErbB2 and ErbB3 oligonucleotides: 
Eight custom oligonucleotides were synthesized (Invitrogen), including both forward and 
reverse strands of the wild type (wt) and mutant (mut) ErbB2 as well as ErbB3 3’UTR segments. 
Each annealed oligonucleotide pair on the 5’-end was synthesized with a blunt DraI restriction 
enzyme recognition sequence followed by an internal full NotI restriction enzyme recognition 
sequence, the requisite ErbB2 or ErbB3 3’UTR sequence and a 3’-end sticky XbaI restriction 
enzyme recognition sequence for proper insertion into the multiple cloning site (digested with 
DraI/XbaI) of the pmiRGlo vector (Promega). Figure 4-3 displays the ErbB2 and ErbB3 wt and 
mut oligonucleotides synthesized for insertion into the pmiRGlo vector (Promega). A three base 
pair mutation within the miR125b seed binding region (bases 2-4) was achieved by changing 
GGG to TTT.  
The lyophilized oligos were re-suspended in TE buffer to a final concentration of 200uM 
and stored at -20◦C. Oligonucleotides were annealed in a 20ul reaction containing 5ul each of a 
forward and reverse strand, 2ul of 10X Oligo annealing buffer (100mM Tris-HCL, 10mM 
EDTA, 1M NaCl) and 8ul of DNAse/RNAse free water. Annealing was accomplished by 
incubation at 95◦C for 4 minutes on a heat block, followed by gradual cooling at room 
temperature for one hour. Annealed oligos were stored at -20◦C. 
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Figure 4-3: ErbB2 and ErbB3 wild type and mutant synthesized oligonucleotides: 
Each annealed oligonucleotide pair on the 5’-end was synthesized with a blunt DraI restriction 
enzyme recognition sequence followed by an internal full NotI restriction enzyme recognition 
sequence, the requisite ErbB2 or ErbB3 3’UTR sequence and a 3’-end sticky XbaI restriction 
enzyme recognition sequence for proper insertion into the multiple cloning site (digested with 
DraI/XbaI) of the pmiRGlo vector (Promega). A three base pair mutation within the miR125b 
seed binding region (bases 2-4) was achieved by changing GGG to TTT.  
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Figure 4-3: ErbB2 and ErbB3 wild type and mutant synthesized oligonucleotides: 
 
DraI-Restriction site 
NotI-Blunt end 
XbaI-Sticky end 
miR125b target site 
miR125b target mutation 
 
   
 
 
 
 
 
ErbB2wt: 
5’– AAACTAGCGGCCGCAGGCCAAGTCCGCAGAAGCCCTGATGTGTCCTCAGGGAGCAGGGAAGGT     -3’ 
3’– TTTGATCGCCGGCGTCCGGTTCAGGCGTCTTCGGGACTACACAGCAGTCCCTCGTCCCTTCCAGATC -5’ 
ErbB2mut: 
5’– AAACTAGCGGCCGCAGGCCAAGTCCGCAGAAGCCCTGATGTGTCCTCATTTAGCAGGGAAGGT     -3’ 
3’– TTTGATCGCCGGCGTCCGGTTCAGGCGTCTTCGGGACTACACAGCAGTAAATCGTCCCTTCCAGATC -5’ 
ErbB3wt: 
5’- AAACTAGCGGCCGCCTCCTGCTCCCTGTGGCACTCAGGGATTAGGGAATGGATAAGAGTGCCT     -3’ 
3’- TTTGATCGCCGGCGGAGGACGAGGGACACCGTGAGTCCCTAATCCCTTACCTATTCTCACGGAGATC -5’ 
ErbB3mut: 
5’- AAACTAGCGGCCGCCTCCTGCTCCCTGTGGCACTCATTTATTAGGGAATGGATAAGAGTGCCT     -3’ 
3’- TTTGATCGCCGGCGGAGGACGAGGGACACCGTGAGTAAATAATCCCTTACCTATTCTCACGGAGATC -5’ 
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ErbB2 and ErbB3 plasmid cloning: 
 The pmiRGlo vector (2µg) was digested with 2-units of DraI (New England Biolabs - 
NEB), 2 units of XbaI (NEB) in NEB buffer 4 with 1xBovine Serum Albumin (‘BSA’ from 
NEB) and brought up to a 20µl reaction volume with DNAse/RNAse free water. The sample was 
incubated in a water bath at 37◦C for 1 hour and 30 minutes. Heat inactivation of the enzymes 
was achieved by heating the sample for 20 minutes on a heat block at 65◦C. The ligation reaction 
was set up so that there was an 8:1 insert (400ng) to vector (50ng) ratio. In a reaction volume of 
20µl, the mixture contained 1xT4 DNA Ligase buffer (NEB) and 2-units of T4 DNA ligase 
(NEB). The sample was incubated at 25◦C for 1 hour. 
 Competent DH5-alpha E. coli cells (50 l) were transformed with the ligation mixture 
(10 l). Transformation was accomplished by incubation on ice for 30 minutes, followed by a 45 
second heat-shock at 42◦C and then 2 minutes on ice. Pre-warmed (37◦C) Luria Broth (LB) 
media (950µl) was added to each mixture and incubated for 1 hour (37◦C with 225 rpm). Colony 
selection was accomplished by plating 200ul and 50ul of each transformation onto 
LB+Ampicillin (0.1µg/ml) plates and incubated overnight at 37◦C. Single colonies from each 
transformation were selected and used to inoculate 250ml of LB+Ampicillin media (0.1µg/ml) 
per sample and incubated overnight (37◦C with 225 rpm). Maxipreps of the inoculates were 
performed using the PowerPrep Plasmid Purification Kit from Origene with integrated pre-filters 
following the manufacturer’s protocol. The DNA sequence of the various 3’UTR inserts was 
verified by the Nucleic Acids Research Facilities (NARF) at Virginia Commonwealth 
University.  
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Cell line Transfections with ErbB2 and ErbB3 wild type and mutated 3’UTRs: 
 P69 and M12+miR17-3p cell lines were transfected with the entire 3’UTR of ErbB2 and 
ErbB3 inserted into the XbaI restriction site of the PGL3 promoter vector (PGL3 vector +3'UTR 
of pErbB2 or pErbB3) fused 3’- to the firefly luciferase gene. The constructs were provided to us 
by Dr. Christopher C. Benz at the Buck Institute for Age Research, Novato, CA 20. In addition, 
the P69 cell line was transfected either with the wild type or mutated 3’UTR constructs of ErbB2 
and ErbB3  inserted into the pmiRGlo vector as previously described. Prior to transfection, 
200,000 actively growing cells were plated per well in triplicate on a 6 well plate and cultured at 
37◦C for 24 hours.  Cells were cultured and passed at least twice before transfection and counted 
using a Beckman-Coulter particle counter.  
Transfection was accomplished with TransIT transfection reagent from Mirus (2µg 
TransIT/ng DNA) and incubated at room temperature for 5 minutes with serum free RPMI 1640 
media plus L-glutamine (Sigma-Aldrich). For the PGL3 constructs, purified plasmid (1µg) either 
PGL3 vector with no insert or PGL3 vector plus pErbB2 or pErbB3 3’UTRs was complexed 
with transfection reagent plus the renilla luciferase control reporter vector (15ng). The optimal 
ratios of PGL3 and renilla plasmid were previously determined
31
. For the pmiRGlo constructs, 
purified plasmid (250ng) was complexed with transfection reagent creating these test samples, 
pmiRGlo with no insert or pmiRGlo with pErbB2wt, pErbB2mut, pErbB3wt or pErbB3mut 
3’UTRs. Each sample was incubated for 30 minutes at room temperature. Fresh media as 
previously described for each cell type was added to each well and the TransIT/RPMI/plasmid 
mixture was dripped over each well shaking gently side to side. The amount of DNA utilized for 
the pmiRGlo vector and incubation time were determined empirically and found to produce the 
most favorable results. 
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After 48 hours of incubation at 37◦C, the cells were lysed for 30 minutes directly on the 
plate with passive lysis buffer (Promega). Cell lysates were stored at -80◦C for ~24 hours. 
Reporter activity was measured using the Promega Dual Luceriferase Assay Kit. Cell lysates and 
reagents were warmed to room temperature per manufacturer’s instructions.  Reporter activity 
(firefly luciferase) was quantified using 30µl of the cell lysate plus 30µl of the luciferase assay 
reagent II (LAR II) and measured with a Glowmax Luminometer. Control reporter activity 
(Renilla luciferase) was assayed in the same manner after the addition of 30µl of the Stop & 
Glow reagent. Reporter activity is presented as a ratio of firefly luciferase to renilla luciferase 
activity.  
Findings of the ErbB2 and ErbB3 Transfections in P69 cells: 
  The P69 cell lines were first transfected with the PGL3 plasmids containing the entire 
ErbB2 or ErbB3 3’UTR  sequence to determine if an actual affect was detected within our 
prostate cancer progression model (Figure 4-4).  The non-metastatic P69 cell line was chosen 
since this cell type exhibits a higher level of miR17-3p expression compared to the M12 cell line. 
A 2.8-fold or 2.4-fold decrease in expression was observed when comparing the mean expression 
of the PGL3 empty vector to the mean expression of the pErbB2 or pErbB3 3’UTR containing 
vectors respectively. Based on these results, translation of both the ErbB2 and ErbB3 mRNAs 
are being influenced by some non-coding RNA molecule that is binding within the respective 
3’UTRs.    
The P69 cell line was also transfected with the pmiRGlo vector containing ErbB2wt, 
ErbB3mut, ErbB3wt and ErbB3mut 3’UTR sequence to determine if miR125b is directly 
targeting ErbB2 or ErbB3 mRNAs within our prostate cancer progression model. Figure 4-5    
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Figure 4-4: The 3’UTRs of pErbB2 and pErbB3 repress luciferase reporter activity.  
P69 cells (200,000 cells per well) were transfected in triplicate with 1µg of PGL3 empty vector, 
or vector containing the entire pErbB2 or pErbB3 3'UTR sequences.  Luciferase activity was 
measured 48 hrs later and expressed as the ratio of firefly to renilla. Standard deviation within 
each sample is shown.  
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Figure 4-4: The 3’UTRs of pErbB2 and pErbB3 repress luciferase reporter activity. 
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Figure 4-5: miR125b does not directly affect luciferase expression of ErbB2 and ErbB3 wt 
and mut vectors in the P69 cell line. 
P69 cells (200,000 cells per well) were transfected in triplicate with 250ng of pmiRGlo empty 
vector, pErbB2wt, pErbB2mut, pErbB3wt or pErbB3mut plasmids. Luciferase activity was 
measured 48 hrs later and expressed as the ratio of firefly to renilla. Standard deviation within 
each sample is shown.  
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Figure 4-5: miR125b does not directly affect luciferase expression of ErbB2 and ErbB3 wt 
and mut vectors in the P69 cell line. 
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depicts the results from the transfections of pmiRGlo, pErbB2wt, pErbB2mut, pErbB3wt and 
pErbB3mut in the P69 cell line. The P69 cell line was chosen because it has the highest 
endogenous expression of miR125b in our prostate cancer progression model.  If there was a 
direct interaction between miR125b and the ErbB2 and ErbB3 3’UTRs we would have expected 
a decrease in luciferase expression between pmiRGlo and the pErbB2wt or pErbB3wt. Based on 
these results, no direct binding within the 3’UTRs of ErbB2 and ErbB3 at the miR125b proposed 
binding sites identified by Scott et al could be detected by this assay method 20.  
The potential for miR17-3p to target ErbB2 or ErbB3:  
In addition to our computational networks identification of the ErbB family of proteins as 
key players in the development/progression of prostate cancer, our proteomics analysis of the 
prostate cancer progression model showed that ErbB2 and ErbB3 are significantly dysregulated 
between M12→M12+miR-17-3p. Based on these results, we propose miR17-3p may directly 
bind to the 3’UTRs of either or both ErbB2 and ErbB3, which would identify a new 
miRNA/target interaction. 
Computational analysis of ErbB2 and ErbB3 3’UTRs and miR17-3p: 
The sequence for miR17-3p was obtained from miRBase  57, 58.The miR17-3p sequence 
and 3’UTR sequences of ErbB2 and ErbB3 were submitted to RNAhybrid, a miRNA/RNA 
minimum free energy structural hybridization prediction tool, using the default settings 59. Figure 
4-6 depicts the predicted structural interaction of miR17-3p and the 3’ UTRs of ErbB2/ErbB3.  
Many of the proven miRNA binding sites have near perfect seed region (bases 2-8) Watson-
Crick binding, adequate minimum free energy of formation (deltaG < -20.0 kcal/mol), and some  
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Figure 4-6: Predicted miR17-3p coupling with the 3’UTR of ErbB2 or ErbB3. 
The sequences of the complete 3’ UTR of (A) ErbB2 /(B) ErbB3 and the sequence of miR17-3p 
were compared using RNAhybrid to predict potential interactions of miR17-3p (green) with the 
3’ UTRs of ErbB2/ ErbB3 (red) 59.   
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Figure 4-6: Predicted miR17-3p coupling with the ErbB2 or ErbB3 3’UTRs. 
A.  
B.  
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degree of 3’ stabilization. The structure of the proposed binding sites for both proposed miRNAs 
adhere to previously observed characteristics and thus it is reasonable to suspect that these 
interactions would occur in vivo.  
Findings of the ErbB2 and ErbB3 Transfections in M12+miR17-3p cells: 
The M12+miR-17-3p cell line was transfected with the pErbB2 and pErbB3 plasmids to 
elucidate any potential miR17-3p interaction between the ErbB2 and ErbB3 3’UTRs in prostate 
cancer. Figure 4-7 depicts the results from the transfections of PGL3/Renilla, pErbB2/Renilla 
and pErbB3/Renilla in the M12+miR-17-3p cell line. If there was a direct interaction between 
miR17-3p and the ErbB2 and ErbB3 3’UTRs we would have expected a decrease in the ratio of 
firefly to renilla expression between PGL3 and the pErbBs. Based on these results, it was 
concluded that miR17-3p may be indirectly affecting the translation of the ErbB2 and ErbB3 
mRNAs, but no direct binding within the 3'UTRs of pErbB2 or pErbB3 could be detected by this 
assay method.  
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Figure 4-7: miR17-3p does not directly affect luciferase expression of pErBb2 or pErbB3 in 
the M12+miR17-3p cell line. 
 M12+miR17-3p cells (200,000 cells per well) were transfected in triplicate with 1µg of PGL3 
empty vector, pErbB2 or pErbB3 plasmids. Luciferase activity was measured 48 hrs later and 
expressed as the ratio of firefly to renilla. Standard deviation within each sample is shown.  
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Figure 4-7: miR17-3p does not directly affect luciferase expression of pErBb2 or pErbB3 in 
the M12+miR17-3p cell line. 
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Discussion: 
 We took a multifaceted approach, combining a computationally built protein-protein 
interaction network of proteins experimentally proven to be targeted by miRNAs with high 
throughput proteomics to identify key protein targets in prostate cancer. This analysis coupled 
with screening the miRnome enhanced our identification of miRNAs that are dysregulated in 
prostate cancer. To our knowledge, this study is the first to combine all three approaches to 
elucidate new miRNAs and targets contributing to prostate cancer progression.  
Our computational networks approach identified the ErbB family of proteins as highly 
connected nodes and therefore key players in the prostate cancer network. Additionally, 
proteomic analysis of our prostate cancer progression model suggested ErbB2 and ErbB3 as 
significantly dysregulated proteins. Several miRNA array screens substantiated by single miR 
analysis of the P69 and M12 related sublines produced miR125b as being highly differentially 
expressed. Previously, it was suggested that miR125b targets ErbB2 and ErbB3 and functions as 
a tumor suppressor in breast cancer 20. Our results suggest a similar function for miR125b in 
prostate cancer where the differential expression of miR125b could be responsible at least in part 
for the dysregulation of the ErbBs.  
Reporter gene assays were conducted to further explore the relationship between 
miR125b and the ErbBs. Fusion of the entire 3'UTR of either ErbB2 or ErbB3 to the luciferase 
reporter gene resulted in a 2.8-fold and 2.4-fold decrease (respectively) in activity in p69 cells 
compared to the parental PGL3 vector. However, inclusion of the miR125b/ErbB2 or ErbB3 
binding sites as proposed in the Scott et al paper did not produce the luciferase expression 
profiles expected of a miRNA/target interaction 20. Several theories could explain the 
inconsistency between our results and those previously published. Foremost is the fact that the 
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binding site identified in the Scott et al paper was not examined by mutagenesis and therefore 
may be incorrect. Recently, the National Institutes of Health published a manuscript describing 
experimental methods to most accurately validate miRNA targets 60. Here, it was concluded that 
insertion of the entire 3’UTR of the target into the expression vector is necessary to prevent 
unintentional structural changes that may hinder miRNA/target binding. Thus, transfection of a 
plasmid containing the entire 3’UTR fused to a reporter compared to selected base pair mutations 
of just that region targeted by the miRNA seed within the entire 3’UTR is proposed to be a more 
accurate option to prove a miRNA/target interaction. In the case of the Scott et al paper 20, failure 
to specifically mutate just those bases proposed to be targeted by the seed region of miR125b 
fails to prove a specific miR125b interaction, yet numerous papers in the literature refer to this 
paper as proof of ErbB2 or ErbB3/miR125b interaction. However, many researchers have used 
this approach to presumably validate miRNA/mRNA interaction. We found that fusion of just 
the target region or a 3 base pair mutation thereof failed to produce any change in reporter 
activity. In agreement with NIH guidelines this could be due to the inability to correctly 
duplicate a structurally active target region 60.  Alternatively, it may be due to the fact that we 
mutated only 3 of the bases within the target region. It may be necessary to mutate all 6 bases 
within miR125b target site before ruling out the importance of this region as a functional 
miR125b binding site.  
The aforementioned NIH guidelines go on to state that over-expression of the miRNA to 
increase miRNA copy availability is not necessary or "ideal" to validate miRNA/mRNA 
interaction because this could lead to non-physiological interactions 60. When Scott et al 
performed their analysis, they infected their cells with a retrovius expressing a mature miR125b 
sequence to attain high level expression 20. From the NIH guidelines this might not be the most 
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relevant protocol. In our case we used P69 cells which naturally express miR125b at a level 
significantly higher than the M12 cell line. Thus, we were not forced to artificially manipulate 
miR125b expression levels but rather worked within the confines of endogenous expression 
levels.   
 Lastly, deletion of ErbB2 (44 bp) or ErbB3's (22 bp) proposed miR125 binding site in the 
Scott et al paper, produced at best only a 1.4-fold decrease in luciferase activity compared to the 
wild type vector 20. In our case inclusion of the entire 3'UTRs generated a significantly greater 
decrease, 2.4- or 2.8-fold, compared to the PGL3 vector with no insert. Our results suggest 
additional mechanisms of ErbB regulation above those included by the aforementioned deletions. 
The most obvious explanation here is that multiple miR125b binding sites might reside within 
the 3'UTRs of ErbB2 or ErbB3, which in a combinatorial fashion control ErbB expression. The 
contribution of only one of these sites, and maybe not the most functional site, was studied by 
Scoot et al. In fact, further computational examination of the ErbB2 and ErbB3 3’UTRs using 
RNAhybrid, identified a better miR125b binding site to ErB259.  Figure 4-8 depicts a potential 
structure formed with a lower minimum free energy of conformation (-24.4kcal/mol) than that 
exhibited by the Scott region (-21.9 kcal/mol). The structure of the proposed binding site adheres 
to previously observed characteristics and thus it is reasonable to suspect that this interaction 
would occur in vivo. Future experiments including mutation of these relevant seed region target 
bases will be required to determine if this is a functional miR125b binding site. 
Last of all, it is possible that miRNAs in addition to or together with miR125b is 
targeting the ErbBs. Previously, single miRNA analysis showed that miR17-3p is differentially 
expressed in our prostate progression model.  Additional experiments showed that miR17-3p can 
act as a tumor suppressor in vitro and in vivo 31. Proteomic data showed that overexpressing   
 
 
72 
 
Figure 4-8: A better predicted miR125b binding site within the ErbB2 3’UTR. 
RNAhybrid predicted structure of binding between miR125b and the 3’ UTR of ErbB2 59. 
miR125b is represented in green and the 3’UTR of ErbB2 is represented in red. 
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Figure 4-8: Predicted best miR125b coupling with the ErbB2 3’UTR. 
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miR-17-3p in the M12 cell line resulted in a decrease in expression of ErbB2 and ErbB3 
suggesting additional regulation by miR17-3p. However, luciferase assays did not confirm a 
direct interaction between miR17-3p binding and a predicted binding site within ErbB's 3'UTR. 
This suggests that miR17-3p is either binding to another unknown site or is affecting the 
expression of a secondary molecule which in turn affects ErbB2 or ErbB3 expression. Although 
miR17-3p's direct interaction on the ErbBs could not be confirmed as yet, our miR screen 
analysis does suggest many miRs that are differentially expressed in the various cell lines of our 
cancer progression model. Thus, there is a strong possibility that additional miRNAs targeting 
the ErbBs will be uncovered in the continuation of these studies.  
In summary the compilation of results from a computational networks approach, 
proteomics and miRnome analysis has suggested miR125b and the ErbBs as relevant players in 
prostate cancer progression. Potentially new miRNAs and targets have thus been identified, 
which warrant further study. Prostate cancer is the second most common cancer affecting men 
today and the second leading cause of cancer deaths in American men. Therefore, there is a 
strong need for accurate biomarkers and successful therapeutic treatments in which identification 
of miRNAs and proteins that contribute to prostate cancer progression could prove invaluable to 
combating this disease. 
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